Foghorn Therapeutics announces first patient dosed with FHD-909
PremiumThe FlyFoghorn Therapeutics announces first patient dosed with FHD-909
26d ago
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
Premium
The Fly
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
1M ago
Foghorn Therapeutics appoints Anna Rivkin as CBO
Premium
The Fly
Foghorn Therapeutics appoints Anna Rivkin as CBO
2M ago
Foghorn Therapeutics Unveils Strategic Plans to Investors
PremiumCompany AnnouncementsFoghorn Therapeutics Unveils Strategic Plans to Investors
5M ago
Foghorn Therapeutics prices 12.7M shares at $5.51 in registered direct offering
Premium
The Fly
Foghorn Therapeutics prices 12.7M shares at $5.51 in registered direct offering
6M ago
Foghorn Therapeutics provides update on programs, upcoming milestones
Premium
The Fly
Foghorn Therapeutics provides update on programs, upcoming milestones
6M ago
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
PremiumCompany AnnouncementsFoghorn Therapeutics Unveils Cancer Research Breakthroughs
7M ago
Foghorn Therapeutics Unveils New Investor Presentation
Premium
Company Announcements
Foghorn Therapeutics Unveils New Investor Presentation
8M ago
Foghorn Therapeutics expects cash runway into first half of 2026
Premium
The Fly
Foghorn Therapeutics expects cash runway into first half of 2026
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100